Microbial translocation in the pathogenesis of HIV infection and AIDS

Clinical Microbiology Reviews

Volumn 26, Issue 1, 2013, Pages 2-18

  Marchetti, Giulia ^a   Tincati, Camilla ^a   Silvestri, Guido ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; FATTY ACID BINDING PROTEIN; LIPOPOLYSACCHARIDE; RIFAXIMIN; SALAZOSULFAPYRIDINE; SEVELAMER CARBONATE;

ARTERIAL WALL THICKNESS; ARTICLE; BACTERIAL TRANSLOCATION; CARDIOVASCULAR DISEASE; COMORBIDITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GASTROINTESTINAL TRANSIT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LIVER DISEASE; MICROBIOME; NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; VIRUS LOAD;

ANIMALS; BACTERIAL TRANSLOCATION; HIV; HIV INFECTIONS; HUMANS; INTESTINAL MUCOSA; MACACA MULATTA; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS;

HUMAN IMMUNODEFICIENCY VIRUS; MACACA MULATTA; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 84872174074     PISSN: 08938512     EISSN: 10986618     Source Type: Journal    
DOI: 10.1128/CMR.00050-12     Document Type: Article

References (153)

1. Douek DC. 2003. Disrupting T-cell homeostasis: how HIV-1 infection causes disease. AIDS Rev. 5:172-177.
2. Cao J, Park IW, Cooper A, Sodroski J. 1996. Molecular determinants of acute single-cell lysis by human immunodeficiency virus type 1. J. Virol. 70:1340-1354.
3. Lenardo MJ, Angleman SB, Bounkeua V, Dimas J, Duvall MG, Graubard MB, Hornung F, Selkirk MC, Speirs CK, Trageser C, Orenstein JO, Bolton DL. 2002. Cytopathic killing of peripheral blood CD4(+) T lymphocytes by human immunodeficiency virus type 1 appears necrotic rather than apoptotic and does not require env. J. Virol. 76:5082-5093.
4. McMichael AJ, Rowland-Jones SL. 2001. Cellular immune responses to HIV. Nature 410:980-987.
5. Deeks SG, Kitchen CM, Liu L, Guo H, Gascon R, Narváez AB, Hunt P, Martin JN, Kahn JO, Levy J, McGrath MS, Hecht FM. 2004. Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood 104:942-947.
6. Lane HC, Masur H, Edgar LC, Whalen G, Rook AH, Fauci AS. 1983. Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N. Engl. J. Med. 309: 453-458.
7. Hellerstein M, Hanley MB, Cesar D, Siler S, Papageorgopoulos C, Wieder E, Schmidt D, Hoh R, Neese R, Macallan D, Deeks S, McCune JM. 1999. Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans. Nat. Med. 5:83-89.
8. Valdez H, Lederman MM. 1997. Cytokines and cytokine therapies in HIV infection. AIDS Clin. Rev. 1997-1998:187-228.
9. Douek DC, Roederer M, Koup RA. 2009. Emerging concepts in the immunopathogenesis of AIDS. Annu. Rev. Med. 60:471-484.
10. Grossman Z, Feinberg MB, Paul WE. 1998. Multiple modes of cellular activation and virus transmission in HIV infection: a role for chronically and latently infected cells in sustaining viral replication. Proc. Natl. Acad. Sci. U. S. A. 95:6314-6319.
11. Giorgi JV, Hultin LE, McKeating JA, Johnson TD, Owens B, Jacobson LP, Shih R, Lewis J, Wiley DJ, Phair JP, Wolinsky SM, Detels R. 1999. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J. Infect. Dis. 179:859-870.
12. Hunt PW, Brenchley J, Sinclair E, McCune JM, Roland M, Page- Shafer K, Hsue P, Emu B, Krone M, Lampiris H, Douek D, Martin JN, Deeks SG. 2008. Relationship between T cell activation and CD4_T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J. Infect. Dis. 197:126-133.
13. Hunt PW, Martin JN, Sinclair E, Bredt B, Hagos E, Lampiris H, Deeks SG. 2003. T cell activation is associated with lower CD4_ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J. Infect. Dis. 187:1534-1543.
14. Marchetti G, Gori A, Casabianca A, Magnani M, Franzetti F, Clerici M, Perno CF, Monforte A, Galli M, Meroni L. 2006. Comparative analysis of T-cell turnover and homeostatic parameters in HIV-infected patients with discordant immune-virological responses to HAART. AIDS 20:1727-1736.
15. Paiardini M, Pandrea I, Apetrei C, Silvestri G. 2009. Lessons learned from the natural hosts of HIV-related viruses. Annu. Rev. Med. 60:485-495.
16. Sodora DL, Silvestri G. 2008. Immune activation and AIDS pathogenesis. AIDS 22:439-446.
17. Paiardini M, Cervasi B, Reyes-Aviles E, Micci L, Ortiz AM, Chahroudi A, Vinton C, Gordon SN, Bosinger SE, Francella N, Hallberg PL, Cramer E, Schlub T, Chan ML, Riddick NE, Collman RG, Apetrei C, Pandrea I, Else J, Munch J, Kirchhoff F, Davenport MP, Brenchley JM, Silvestri G. 2011. Low levels of SIV infection in sooty mangabey central memory CD4+ T cells are associated with limited ccr5 expression. Nat. Med. 17:830-836.
18. Wolochow H, Hildebrand GJ, Lamanna C. 1966. Translocation of microorganisms across the intestinal wall of the rat: effect of microbial size and concentration. J. Infect. Dis. 116:523-528.
19. Fuller R, Jayne-Williams DJ. 1970. Resistance of the fowl (Gallus domesticus) to invasion by its intestinal flora. I. The effect of hormonal bursectomy on the invasiveness of the intestinal microflora of the fowl. Res. Vet. Sci. 11:363-367.
20. Fuller R, Jayne-Williams DJ. 1970. Resistance of the fowl (Gallus domesticus) to invasion by its intestinal flora. II. Clearance of translocated intestinal bacteria. Res. Vet. Sci. 11:368-374.
21. Berg RD. 1995. Bacterial translocation from the gastrointestinal tract. Trends Microbiol. 3:149-154.
22. Alexander JW, Gianotti L, Pyles T, Carey MA, Babcock GF. 1991. Distribution and survival of Escherichia coli translocating from the intestine after thermal injury. Ann. Surg. 213:558-566. discussion 566-567.
23. Tancrède CH, Andremont AO. 1985. Bacterial translocation and gramnegative bacteremia in patients with hematological malignancies. J. Infect. Dis. 152:99-103.
24. Beutler B. 2000. Tlr4: central component of the sole mammalian LPS sensor. Curr. Opin. Immunol. 12:20-26.
25. Caradonna L, Amati L, Magrone T, Pellegrino NM, Jirillo E, Caccavo D. 2000. Enteric bacteria, lipopolysaccharides and related cytokines in inflammatory bowel disease: biological and clinical significance. J. Endotoxin Res. 6:205-214.
26. Cooke KR, Gerbitz A, Crawford JM, Teshima T, Hill GR, Tesolin A, Rossignol DP, Ferrara JL. 2001. LPS antagonism reduces graft-versushost disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation. J. Clin. Invest. 107:1581-1589.
27. Schietroma M, Carlei F, Cappelli S, Amicucci G. 2006. Intestinal permeability and systemic endotoxemia after laparotomic or laparoscopic cholecystectomy. Ann. Surg. 243:359-363.
28. Barclay GR, Scott BB, Wright IH, Rogers PN, Smith DG, Poxton IR. 1989. Changes in anti-endotoxin-IgG antibody and endotoxaemia in three cases of gram-negative septic shock. Circ. Shock 29:93-106.
29. Anderson KV. 2000. Toll signaling pathways in the innate immune response. Curr. Opin. Immunol. 12:13-19.
30. Liu Y, van Kruiningen HJ, West AB, Cartun RW, Cortot A, Colombel JF. 1995. Immunocytochemical evidence of Listeria, Escherichia coli, and Streptococcus antigens in Crohn's disease. Gastroenterology 108: 1396-1404.
31. Eriguchi Y, Takashima S, Oka H, Shimoji S, Nakamura K, Uryu H, Shimoda S, Iwasaki H, Shimono N, Ayabe T, Akashi K, Teshima T. 2012. Graft-versus-host disease disrupts intestinal microbial ecology by inhibiting paneth cell production of _-defensins. Blood 120:223-231.
32. Brenchley JM, Price DA, Douek DC. 2006. HIV disease: fallout from a mucosal catastrophe? Nat. Immunol. 7:235-239.
33. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, Kazzaz Z, Bornstein E, Lambotte O, Altmann D, Blazar BR, Rodriguez B, Teixeira-Johnson L, Landay A, Martin JN, Hecht FM, Picker LJ, Lederman MM, Deeks SG, Douek DC. 2006. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat. Med. 12:1365-1371.
34. Guadalupe M, Reay E, Sankaran S, Prindiville T, Flamm J, McNeil A, Dandekar S. 2003. Severe CD4+T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J. Virol. 77:11708-11717.
35. Mehandru S, Poles MA, Tenner-Racz K, Horowitz A, Hurley A, Hogan C, Boden D, Racz P, Markowitz M. 2004. Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J. Exp. Med. 200: 761-770.
36. Pelsers MM, Namiot Z, Kisielewski W, Namiot A, Januszkiewicz M, Hermens WT, Glatz JF. 2003. Intestinal-type and liver-type fatty acidbinding protein in the intestine. Tissue distribution and clinical utility. Clin. Biochem. 36:529-535.
37. Sandler NG, Wand H, Roque A, Law M, Nason MC, Nixon DE, Pedersen C, Ruxrungtham K, Lewin SR, Emery S, Neaton JD, Brenchley JM, Deeks SG, Sereti I, Douek DC, INSIGHT SMART Study Group. 2011. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J. Infect. Dis. 203:780-790.
38. Mavigner M, Cazabat M, Dubois M, L'Faqihi FE, Requena M, Pasquier C, Klopp P, Amar J, Alric L, Barange K, Vinel JP, Marchou B, Massip P, Izopet J, Delobel P. 2012. Altered CD4+ T cell homing to the gut impairs mucosal immune reconstitution in treated HIV-infected individuals. J. Clin. Invest. 122:62-69.
39. Marchetti G, Bellistrì GM, Borghi E, Tincati C, Ferramosca S, La Francesca M, Morace G, Gori A, Monforte AD. 2008. Microbial translocation is associated with sustained failure in CD4+ T-cell reconstitution in HIV-infected patients on long-term highly active antiretroviral therapy. AIDS 22:2035-2038.
40. Merlini E, Bai F, Bellistrì GM, Tincati C, d'Arminio Monforte A, Marchetti G. 2011. Evidence for polymicrobic flora translocating in peripheral blood of HIV-infected patients with poor immune response to antiretroviral therapy. PLoS One 6:e18580. doi:10.1371/ journal.pone.0018580.
41. Marchetti G, Cozzi-Lepri A, Merlini E, Bellistrì GM, Castagna A, Galli M, Verucchi G, Antinori A, Costantini A, Giacometti A, di Caro A, D'Arminio Monforte A, ICONA Foundation Study Group. 2011. Microbial translocation predicts disease progression of HIV-infected antiretroviral- naive patients with high CD4+ cell count. AIDS 25:1385-1394.
42. Bukh AR, Melchjorsen J, Offersen R, Jensen JM, Toft L, Støvring H, Ostergaard L, Tolstrup M, Søgaard OS. 2011. Endotoxemia is associated with altered innate and adaptive immune responses in untreated HIV-1 infected individuals. PLoS One 6:e21275. doi:10.1371/ journal.pone.0021275.
43. Papasavvas E, Pistilli M, Reynolds G, Bucki R, Azzoni L, Chehimi J, Janmey PA, DiNubile MJ, Ondercin J, Kostman JR, Mounzer KC, Montaner LJ. 2009. Delayed loss of control of plasma lipopolysaccharide levels after therapy interruption in chronically HIV-1-infected patients. AIDS 23:369-375.
44. Baroncelli S, Galluzzo CM, Pirillo MF, Mancini MG, Weimer LE, Andreotti M, Amici R, Vella S, Giuliano M, Palmisano L. 2009. Microbial translocation is associated with residual viral replication in HAART-treated HIV+subjects with<50copies/ml HIV-1 RNA. J. Clin. Virol. 46:367-370.
45. Jiang W, Lederman MM, Hunt P, Sieg SF, Haley K, Rodriguez B, Landay A, Martin J, Sinclair E, Asher AI, Deeks SG, Douek DC, Brenchley JM. 2009. Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J. Infect. Dis. 199:1177-1185.
46. Kramski M, Gaeguta AJ, Lichtfuss GF, Rajasuriar R, Crowe SM, French MA, Lewin SR, Center RJ, Purcell DF. 2011. Novel sensitive real-time PCR for quantification of bacterial 16S rRNA genes in plasma of HIV-infected patients as a marker for microbial translocation. J. Clin. Microbiol. 49:3691-3693.
47. Nixon DE, Landay AL. 2010. Biomarkers of immune dysfunction in HIV. Curr. Opin. HIV AIDS 5:498-503.
48. Fukui H, Brauner B, Bode JC, Bode C. 1989. Chromogenic endotoxin assay in plasma. Selection of plasma pretreatment and production of standard curves. J. Clin. Chem. Clin. Biochem. 27:941-946.
49. Drancourt M, Bollet C, Carlioz A, Martelin R, Gayral JP, Raoult D. 2000. 16S ribosomal DNA sequence analysis of a large collection of environmental and clinical unidentifiable bacterial isolates. J. Clin. Microbiol. 38:3623-3630.
50. Janda JM, Abbott SL. 2007. 16S rRNA gene sequencing for bacterial identification in the diagnostic laboratory: pluses, perils, and pitfalls. J. Clin. Microbiol. 45:2761-2764.
51. Amar J, Fauvel J, Drouet L, Ruidavets JB, Perret B, Chamontin B, Boccalon H, Ferrieres J. 2006. Interleukin 6 is associated with subclinical atherosclerosis: a link with soluble intercellular adhesion molecule 1. J. Hypertens. 24:1083-1088.
52. Ferri E, Novati S, Casiraghi M, Sambri V, Genco F, Gulminetti R, Bandi C. 2010. Plasma levels of bacterial DNA in HIV infection: the limits of quantitative polymerase chain reaction. J. Infect. Dis. 202:176-177. author reply 178.
53. Böttger EC. 1990. Frequent contamination of Taq polymerase with DNA. Clin. Chem. 36:1258-1259.
54. Corless CE, Guiver M, Borrow R, Edwards-Jones V, Kaczmarski EB, Fox AJ. 2000. Contamination and sensitivity issues with a real-time universal 16S rRNA PCR. J. Clin. Microbiol. 38:1747-1752.
55. Handschur M, Karlic H, Hertel C, Pfeilstöcker M, Haslberger AG. 2009. Preanalytic removal of humanDNAeliminates false signals in general 16s rDNA PCR monitoring of bacterial pathogens in blood. Comp. Immunol. Microbiol. Infect. Dis. 32:207-219.
56. Abdurahman A, Barqasho B, Nowak P, Cuong DD, Amogne W, Troseid M, Vesterbacka J, Sönnerborg A. 2011. Elevated flagellinspecific antibodies during HIV-1 infection, abstr 313. Abstr. 18th Conf. Retroviruses Opportun. Infect., Boston, MA.
57. Barqasho B, Abdurahman A, Nowak P, Vesterbacka J, Andersson LM, Svärd J, Trosseid M, Gisslén M, Sönnerborg A. 2012. Longitudinal analysis of microbial translocation markers in patients on efavirenz or lopinavir/r based antiretroviral therapy, abstr 836. Abstr. 19th Conf. Retroviruses Opportun. Infect., Seattle, WA.
58. Giorgi JV, Lyles RH, Matud JL, Yamashita TE, Mellors JW, Hultin LE, Jamieson BD, Margolick JB, Rinaldo CR, Phair JP, Detels R, Multicenter AIDS Cohort Study. 2002. Predictive value of immunologic and virologic markers after long or short duration of HIV-1 infection. J. Acquir. Immune Defic. Syndr. 29:346-355.
59. Ciccone EJ, Read SW, Mannon PJ, Yao MD, Hodge JN, Dewar R, Chairez CL, Proschan MA, Kovacs JA, Sereti I. 2010. Cycling of gut mucosal CD4+ T cells decreases after prolonged anti-retroviral therapy and is associated with plasma LPS levels. Mucosal Immunol. 3:172-181.
60. Nowroozalizadeh S, Månsson F, da Silva Z, Repits J, Dabo B, Pereira C, Biague A, Albert J, Nielsen J, Aaby P, Fenyö EM, Norrgren H, Holmgren B, Jansson M. 2010. Microbial translocation correlates with the severity of both HIV-1 and HIV-2 infections. J. Infect. Dis. 201:1150-1154.
61. Klatt NR, Harris LD, Vinton CL, Sung H, Briant JA, Tabb B, Morcock D, McGinty JW, Lifson JD, Lafont BA, Martin MA, Levine AD, Estes JD, Brenchley JM. 2010. Compromised gastrointestinal integrity in pigtail macaques is associated with increased microbial translocation, immune activation, and IL-17 production in the absence of SIV infection. Mucosal Immunol. 3:387-398.
62. Cassol E, Malfeld S, Mahasha P, van der Merwe S, Cassol S, Seebregts C, Alfano M, Poli G, Rossouw T. 2010. Persistent microbial translocation and immune activation in HIV-1-infected South Africans receiving combination antiretroviral therapy. J. Infect. Dis. 202:723-733.
63. Estes JD, Harris LD, Klatt NR, Tabb B, Pittaluga S, Paiardini M, Barclay GR, Smedley J, Pung R, Oliveira KM, Hirsch VM, Silvestri G, Douek DC, Miller CJ, Haase AT, Lifson J, Brenchley JM. 2010. Damaged intestinal epithelial integrity linked to microbial translocation in pathogenic simian immunodeficiency virus infections. PLoS Pathog. 6:e1001052. doi:10.1371/journal.ppat.1001052.
64. Ellis CL, Ma ZM, Mann SK, Li CS, Wu J, Knight TH, Yotter T, Hayes TL, Maniar AH, Troia-Cancio PV, Overman HA, Torok NJ, Albanese A, Rutledge JC, Miller CJ, Pollard RB, Asmuth DM. 2011. Molecular characterization of stool microbiota in HIV-infected subjects by panbacterial and order-level 16S ribosomal DNA (rDNA) quantification and correlations with immune activation. J. Acquir. Immune Defic. Syndr. 57:363-370.
65. d'Ettorre G, Paiardini M, Zaffiri L, Andreotti M, Ceccarelli G, Rizza C, Indinnimeo M, Vella S, Mastroianni CM, Silvestri G, Vullo V. 2011. HIV persistence in the gut mucosa of HIV-infected subjects undergoing antiretroviral therapy correlates with immune activation and increased levels of LPS. Curr. HIV Res. 9:148-153.
66. Chege D, Sheth PM, Kain T, Kim CJ, Kovacs C, Loutfy M, Halpenny R, Kandel G, Chun TW, Ostrowski M, Kaul R, Toronto Mucosal Immunology Group. 2011. Sigmoid Th17 populations, the HIV latent reservoir, and microbial translocation in men on long-term antiretroviral therapy. AIDS 25:741-749.
67. Funderburg N, Luciano AA, Jiang W, Rodriguez B, Sieg SF, Lederman MM. 2008. Toll-like receptor ligands induce human T cell activation and death, a model for HIV pathogenesis. PLoS One 3:e1915. doi:10.1371/ journal.pone.0001915.
68. Tincati C, Bellistrì GM, Ancona G, Merlini E, d'Arminio Monforte A, Marchetti G. 2012. Role of in vitro stimulation with lipopolysaccharide on T-cell activation in HIV-infected antiretroviral-treated patients. Clin. Dev. Immunol. 2012:935425. doi:10.1155/2012/935425.
69. Merlini E, Tincati C, Bellistri GM, Bai F, d'Arminio Monforte A, Marchetti G. 2012. Stimulation with microbial components accounts for different levels of activation and HIV production in T cells and macrophages according to the severity of CD4 impairment, abstr 5. Abstr. 8th Int. Workshop HIV Cells Macrophage/Dendritic Lineage Other Reservoirs Pathogenic Ther. Implications, Stresa, Italy.
70. Mattapallil JJ, Douek DC, Hill B, Nishimura Y, Martin M, Roederer M. 2005. Massive infection and loss of memory CD4+T cells in multiple tissues during acute SIV infection. Nature 434:1093-1097.
71. Brenchley JM, Schacker TW, Ruff LE, Price DA, Taylor JH, Beilman GJ, Nguyen PL, Khoruts A, Larson M, Haase AT, Douek DC. 2004. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J. Exp. Med. 200:749-759.
72. Veazey RS, DeMaria M, Chalifoux LV, Shvetz DE, Pauley DR, Knight HL, Rosenzweig M, Johnson RP, Desrosiers RC, Lackner AA. 1998. Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science 280:427-431.
73. Kewenig S, Schneider T, Hohloch K, Lampe-Dreyer K, Ullrich R, Stolte N, Stahl-Hennig C, Kaup FJ, Stallmach A, Zeitz M. 1999. Rapid mucosal CD4(+) T-cell depletion and enteropathy in simian immunodeficiency virus-infected rhesus macaques. Gastroenterology 116:1115-1123.
74. Smit-McBride Z, Mattapallil JJ, McChesney M, Ferrick D, Dandekar S. 1998. Gastrointestinal T lymphocytes retain high potential for cytokine responses but have severe CD4(+) T-cell depletion at all stages of simian immunodeficiency virus infection compared to peripheral lymphocytes. J. Virol. 72:6646-6656.
75. Verhoeven D, Sankaran S, Silvey M, Dandekar S. 2008. Antiviral therapy during primary simian immunodeficiency virus infection fails to prevent acute loss of CD4+ T cells in gut mucosa but enhances their rapid restoration through central memory T cells. J. Virol. 82:4016-4027.
76. Sankaran S, George MD, Reay E, Guadalupe M, Flamm J, Prindiville T, Dandekar S. 2008. Rapid onset of intestinal epithelial barrier dysfunction in primary human immunodeficiency virus infection is driven by an imbalance between immune response and mucosal repair and regeneration. J. Virol. 82:538-545.
77. Li Q, Estes JD, Duan L, Jessurun J, Pambuccian S, Forster C, Wietgrefe S, Zupancic M, Schacker T, Reilly C, Carlis JV, Haase AT. 2008. Simian immunodeficiency virus-induced intestinal cell apoptosis is the underlying mechanism of the regenerative enteropathy of early infection. J. Infect. Dis. 197:420-429.
78. Gordon SN, Klatt NR, Bosinger SE, Brenchley JM, Milush JM, Engram JC, Dunham RM, Paiardini M, Klucking S, Danesh A, Strobert EA, Apetrei C, Pandrea IV, Kelvin D, Douek DC, Staprans SI, Sodora DL, Silvestri G. 2007. Severe depletion of mucosal CD4+T cells in AIDS-free simian immunodeficiency virus-infected sooty mangabeys. J. Immunol. 179:3026-3034.
79. Pandrea IV, Gautam R, Ribeiro RM, Brenchley JM, Butler IF, Pattison M, Rasmussen T, Marx PA, Silvestri G, Lackner AA, Perelson AS, Douek DC, Veazey RS, Apetrei C. 2007. Acute loss of intestinal CD4+ T cells is not predictive of simian immunodeficiency virus virulence. J. Immunol. 179:3035-3046.
80. Paiardini M, Frank I, Pandrea I, Apetrei C, Silvestri G. 2008. Mucosal immune dysfunction in AIDS pathogenesis. AIDS Rev. 10:36-46.
81. Brenchley JM, Paiardini M, Knox KS, Asher AI, Cervasi B, Asher TE, Scheinberg P, Price DA, Hage CA, Kholi LM, Khoruts A, Frank I, Else J, Schacker T, Silvestri G, Douek DC. 2008. Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections. Blood 112:2826-2835.
82. Brenchley JM, Knox KS, Asher AI, Price DA, Kohli LM, Gostick E, Hill BJ, Hage CA, Brahmi Z, Khoruts A, Twigg HL, Schacker TW, Douek DC. 2008. High frequencies of polyfunctional HIV-specific T cells are associated with preservation of mucosal CD4 T cells in bronchoalveolar lavage. Mucosal Immunol. 1:49-58.
83. Cecchinato V, Trindade CJ, Laurence A, Heraud JM, Brenchley JM, Ferrari MG, Zaffiri L, Tryniszewska E, Tsai WP, Vaccari M, Parks RW, Venzon D, Douek DC, O'Shea JJ, Franchini G. 2008. Altered balance between Th17 and Th1 cells at mucosal sites predicts AIDS progression in simian immunodeficiency virus-infected macaques. Mucosal Immunol. 1:279-288.
84. Nigam P, Kwa S, Velu V, Amara RR. 2011. Loss of IL-17-producing CD8 T cells during late chronic stage of pathogenic simian immunodeficiency virus infection. J. Immunol. 186:745-753.
85. Reeves RK, Rajakumar PA, Evans TI, Connole M, Gillis J, Wong FE, Kuzmichev YV, Carville A, Johnson RP. 2011. Gut inflammation and indoleamine deoxygenase inhibit IL-17 production and promote cytotoxic potential in NKp44+mucosalNKcells during SIV infection. Blood 118:3321-3330.
86. Klatt NR, Estes JD, Sun X, Ortiz AM, Barber JS, Harris LD, Cervasi B, Yokomizo LK, Pan L, Vinton CL, Tabb B, Canary LA, Dang Q, Hirsch VM, Alter G, Belkaid Y, Lifson JD, Silvestri G, Milner JD, Paiardini M, Haddad EK, Brenchley JM. 2012. Loss of mucosal CD103+ DCs and IL-17+ and IL-22+ lymphocytes is associated with mucosal damage in SIV infection. Mucosal Immunol. 5:646-657.
87. Favre D, Lederer S, Kanwar B, Ma ZM, Proll S, Kasakow Z, Mold J, Swainson L, Barbour JD, Baskin CR, Palermo R, Pandrea I, Miller CJ, Katze MG, McCune JM. 2009. Critical loss of the balance between Th17 and T regulatory cell populations in pathogenic SIV infection. PLoS Pathog. 5:e1000295. doi:10.1371/journal.ppat.1000295.
88. Kao CY, Chen Y, Thai P, Wachi S, Huang F, Kim C, Harper RW, Wu R. 2004. IL-17 markedly up-regulates beta-defensin-2 expression in human airway epithelium via JAK and NF-kappaB signaling pathways. J. Immunol. 173:3482-3491.
89. Liang SC, Tan XY, Luxenberg DP, Karim R, Dunussi-Joannopoulos K, Collins M, Fouser LA. 2006. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J. Exp. Med. 203:2271-2279.
90. Kolls JK, Lindén A. 2004. Interleukin-17 family members and inflammation. Immunity 21:467-476.
91. Pandrea I, Gaufin T, Brenchley JM, Gautam R, Monjure C, Gautam A, Coleman C, Lackner AA, Ribeiro RM, Douek DC, Apetrei C. 2008. Cutting edge: experimentally induced immune activation in natural hosts of simian immunodeficiency virus induces significant increases in viral replication and CD4+ T cell depletion. J. Immunol. 181:6687-6691.
92. Pandrea I, Cornell E, Wilson C, Ribeiro RM, Ma D, Kristoff J, Xu C, Haret-Richter GS, Trichel A, Apetrei C, Landay A, Tracy R. 2012. Coagulation biomarkers predict disease progression in SIV-infected nonhuman primates. Blood 120:1357-1366.
93. Sharpstone D, Neild P, Crane R, Taylor C, Hodgson C, Sherwood R, Gazzard B, Bjarnason I. 1999. Small intestinal transit, absorption, and permeability in patients with AIDS with and without diarrhoea. Gut 45:70-76.
94. Clayton F, Kapetanovic S, Kotler DP. 2001. Enteric microtubule depolymerization in HIV infection: a possible cause of HIV-associated enteropathy. AIDS 15:123-124.
95. Kapembwa MS, Fleming SC, Sewankambo N, Serwadda D, Lucas S, Moody A, Griffin GE. 1991. Altered small-intestinal permeability associated with diarrhoea in human-immunodeficiency-virus-infected Caucasian and African subjects. Clin. Sci. (Lond.) 81:327-334.
96. Kotler DP, Gaetz HP, Lange M, Klein EB, Holt PR. 1984. Enteropathy associated with the acquired immunodeficiency syndrome. Ann. Intern. Med. 101:421-428.
97. Estes JD, Gordon SN, Zeng M, Chahroudi AM, Dunham RM, Staprans SI, Reilly CS, Silvestri G, Haase AT. 2008. Early resolution of acute immune activation and induction of PD-1 in SIV-infected sooty mangabeys distinguishes nonpathogenic from pathogenic infection in rhesus macaques. J. Immunol. 180:6798-6807.
98. Tlaskalová-Hogenová H, Stepánková R, Hudcovic T, Tucková L, Cukrowska B, Lodinová-Zádníková R, Kozáková H, Rossmann P, Bártová J, Sokol D, Funda DP, Borovská D, Reháková Z, Sinkora J, Hofman J, Drastich P, Kokesová A. 2004. Commensal bacteria (normal microflora), mucosal immunity and chronic inflammatory and autoimmune diseases. Immunol. Lett. 93:97-108.
99. Umesaki Y, Okada Y, Matsumoto S, Imaoka A, Setoyama H. 1995. Segmented filamentous bacteria are indigenous intestinal bacteria that activate intraepithelial lymphocytes and induce MHC class II molecules and fucosyl asialo GM1 glycolipids on the small intestinal epithelial cells in the ex-germ-free mouse. Microbiol. Immunol. 39:555-562.
100. Brenchley JM, Douek DC. 2012. Microbial translocation across the GI tract. Annu. Rev. Immunol. 30:149-173.
101. McKenna P, Hoffmann C, Minkah N, Aye PP, Lackner A, Liu Z, Lozupone CA, Hamady M, Knight R, Bushman FD. 2008. The ma- caque gut microbiome in health, lentiviral infection, and chronic enterocolitis. PLoS Pathog. 4:e20. doi:10.1371/journal.ppat.0040020.
102. Gori A, Tincati C, Rizzardini G, Torti C, Quirino T, Haarman M, Ben Amor K, van Schaik J, Vriesema A, Knol J, Marchetti G, Welling G, Clerici M. 2008. Early impairment of gut function and gut flora supporting a role for alteration of gastrointestinal mucosa in human immunodeficiency virus pathogenesis. J. Clin. Microbiol. 46:757-758.
103. Tøn H, Brandsnes, Dale S, Holtlund J, Skuibina E, Schjønsby H, Johne B. 2000. Improved assay for fecal calprotectin. Clin. Chim. Acta 292:41-54.
104. Vaarala O, Atkinson MA, Neu J. 2008. The "perfect storm" for type 1 diabetes: the complex interplay between intestinal microbiota, gut permeability, and mucosal immunity. Diabetes 57:2555-2562.
105. Vijay-Kumar M, Aitken JD, Carvalho FA, Cullender TC, Mwangi S, Srinivasan S, Sitaraman SV, Knight R, Ley RE, Gewirtz AT. 2010. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science 328:228-231.
106. Lin YP, Thibodeaux CH, Peña JA, Ferry GD, Versalovic J. 2008. Probiotic Lactobacillus reuteri suppress proinflammatory cytokines via c-Jun. Inflamm. Bowel Dis. 14:1068-1083.
107. Neaton JD, Neuhaus J, Emery S. 2010. Soluble biomarkers and morbidity and mortality among people infected with HIV: summary of published reports from 1997 to 2010. Curr. Opin. HIV AIDS 5:480-490.
108. Redd AD, Dabitao D, Bream JH, Charvat B, Laeyendecker O, Kiwanuka N, Lutalo T, Kigozi G, Tobian AA, Gamiel J, Neal JD, Oliver AE, Margolick JB, Sewankambo N, Reynolds SJ, Wawer MJ, Serwadda D, Gray RH, Quinn TC. 2009. Microbial translocation, the innate cytokine response, and HIV-1 disease progression in Africa. Proc. Natl. Acad. Sci. U. S. A. 106:6718-6723.
109. Redd AD, Eaton KP, Kong X, Laeyendecker O, Lutalo T, Wawer MJ, Gray RH, Serwadda D, Quinn TC, Rakai Health Sciences Program. 2010. C-reactive protein levels increase during HIV-1 disease progression in Rakai, Uganda, despite the absence of microbial translocation. J. Acquir. Immune Defic. Syndr. 54:556-559.
110. George MD, Sankaran S, Reay E, Gelli AC, Dandekar S. 2003. Highthroughput gene expression profiling indicates dysregulation of intestinal cell cycle mediators and growth factors during primary simian immunodeficiency virus infection. Virology 312:84-94.
111. Stone JD, Heise CC, Miller CJ, Halsted CH, Dandekar S. 1994. Development of malabsorption and nutritional complications in simian immunodeficiency virus-infected rhesus macaques. AIDS 8:1245-1256.
112. Dandekar S. 2007. Pathogenesis of HIV in the gastrointestinal tract. Curr. HIV/AIDS Rep. 4:10-15.
113. Zoufaly A, an der Heiden M, Kollan C, Bogner JR, Fätkenheuer G, Wasmuth JC, Stoll M, Hamouda O, van Lunzen J, ClinSurv Study Group. 2011. Clinical outcome of HIV-infected patients with discordant virological and immunological response to antiretroviral therapy. J. Infect. Dis. 203:364-371.
114. Loutfy MR, Genebat M, Moore D, Raboud J, Chan K, Antoniou T, Milan D, Shen A, Klein MB, Cooper C, Machouf N, Rourke SB, Rachlis A, Tsoukas C, Montaner JS, Walmsley SL, Smieja M, Bayoumi A, Mills E, Hogg RS, CANOC Collaboration. 2010. A CD4+ cell count <200 cells per cubic millimeter at 2 years after initiation of combination antiretroviral therapy is associated with increased mortality in HIVinfected individuals with viral suppression. J. Acquir. Immune Defic. Syndr. 55:451-459.
115. Deeks SG. 2011. HIV infection, inflammation, immunosenescence, and aging. Annu. Rev. Med. 62:141-155.
116. Ancuta P, Kamat A, Kunstman KJ, Kim EY, Autissier P, Wurcel A, Zaman T, Stone D, Mefford M, Morgello S, Singer EJ, Wolinsky SM, Gabuzda D. 2008. Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. PLoS One 3:e2516. doi:10.1371/journal.pone.0002516.
117. Kamat A, Lyons JL, Misra V, Uno H, Morgello S, Singer EJ, Gabuzda D. 2012. Monocyte activation markers in cerebrospinal fluid associated with impaired neurocognitive testing in advanced HIV infection. J. Acquir. Immune Defic. Syndr. 60:234-243.
118. Ellis R, Gelman B, Letendre S, Clifford D, Simpson D, Marra C, McArthur J, McCutchan A, Grant I, the CHARTER Group. 2012. Soluble CD14 in cerebrospinal fluid in HIV sensory neuropathy, abstr 496. Abstr. 19th Conf. Retroviruses Opportun. Infect., Seattle, WA.
119. Forsyth CB, Shannon KM, Kordower JH, Voigt RM, Shaikh M, Jaglin JA, Estes JD, Dodiya HB, Keshavarzian A. 2011. Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease. PLoS One 6:e28032. doi:10.1371/journal.pone.0028032.
120. Jirillo E, Caccavo D, Magrone T, Piccigallo E, Amati L, Lembo A, Kalis C, Gumenscheimer M. 2002. The role of the liver in the response to LPS: experimental and clinical findings. J. Endotoxin Res. 8:319-327.
121. Jerala R. 2007. Structural biology of the LPS recognition. Int. J. Med. Microbiol. 297:353-363.
122. Caradonna L, Mastronardi ML, Magrone T, Cozzolongo R, Cuppone R, Manghisi OG, Caccavo D, Pellegrino NM, Amoroso A, Jirillo E, Amati L. 2002. Biological and clinical significance of endotoxemia in the course of hepatitis C virus infection. Curr. Pharm. Des. 8:995-1005.
123. Balagopal A, Philp FH, Astemborski J, Block TM, Mehta A, Long R, Kirk GD, Mehta SH, Cox AL, Thomas DL, Ray SC. 2008. Human immunodeficiency virus-related microbial translocation and progression of hepatitis C. Gastroenterology 135:226-233.
124. Thurman RG. 1998. II. Alcoholic liver injury involves activation of Kupffer cells by endotoxin. Am. J. Physiol. 275:G605-G611.
125. Paik YH, Schwabe RF, Bataller R, Russo MP, Jobin C, Brenner DA. 2003. Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. Hepatology 37:1043-1055.
126. Rubio-Tapia A, Murray JA. 2007. The liver in celiac disease. Hepatology 46:1650-1658.
127. Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L, Ferrara JL. 1997. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood 90:3204-3213.
128. Feld JJ, Meddings J, Heathcote EJ. 2006. Abnormal intestinal permeability in primary biliary cirrhosis. Dig. Dis. Sci. 51:1607-1613.
129. Marchetti G, Nasta P, Bai F, Gatti F, Bellistrì GM, Tincati C, Borghi F, Carosi G, Puoti M, Monforte A. 2012. Circulating sCD14 is associated with virological response to pegylated-interferon-alpha/ribavirin treatment in HIV/HCV co-infected patients. PLoS One 7:e32028. doi: 10.1371/journal.pone.0032028.
130. Sandler NG, Koh C, Roque A, Eccleston JL, Siegel RB, Demino M, Kleiner DE, Deeks SG, Liang TJ, Heller T, Douek DC. 2011. Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection. Gastroenterology 141:1220-1230. e3. doi:10.1053/j.gastro.2011.06.063.
131. McGovern BH. 2007. Hepatitis C in the HIV-infected patient. J. Acquir. Immune Defic. Syndr. 45(Suppl 2):S47-S56 discussion S66-S67. doi: 10.1097/QAI.0b013e318068d190.
132. Gonzalez VD, Falconer K, Blom KG, Reichard O, Mørn B, Laursen AL, Weis N, Alaeus A, Sandberg JK. 2009. High levels of chronic immune activation in the T-cell compartments of patients coinfected with hepatitis C virus and human immunodeficiency virus type 1 and on highly active antiretroviral therapy are reverted by alpha interferon and ribavirin treatment. J. Virol. 83:11407-11411.
133. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. 2009. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461:399-401.
134. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, Bochud M, Battegay M, Bernasconi E, Borovicka J, Colombo S, Cerny A, Dufour JF, Furrer H, Günthard HF, Heim M, Hirschel B, Malinverni R, Moradpour D, Müllhaupt B, Witteck A, Beckmann JS, Berg T, Bergmann S, Negro F, Telenti A, Bochud PY, Swiss Hepatitis C Cohort Study, Swiss HIV Cohort Study. 2010. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 138:1338-1345. e7. doi:10.1053/j.gastro.2009.12.056.
135. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, Müller T, Bahlo M, Stewart GJ, Booth DR, George J. 2009. IL28B is associated with response to chronic hepatitisCinterferon- alpha and ribavirin therapy. Nat. Genet. 41:1100-1104.
136. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A, Hiasa Y, Nishiguchi S, Koike A, Sakaida I, Imamura M, Ito K, Yano K, Masaki N, Sugauchi F, Izumi N, Tokunaga K, Mizokami M. 2009. Genome- wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat. Genet. 41:1105-1109.
137. Dill MT, Duong FH, Vogt JE, Bibert S, Bochud PY, Terracciano L, Papassotiropoulos A, Roth V, Heim MH. 2011. Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology 140:1021-1031.
138. Wurfel MM, Hailman E, Wright SD. 1995. Soluble CD14 acts as a shuttle in the neutralization of lipopolysaccharide (LPS) by LPS-binding protein and reconstituted high density lipoprotein. J. Exp. Med. 181: 1743-1754.
139. Marchetti G, Cozzi-Lepri A, Bellistri GM, Merlini E, Ceccherini- Silberstein F, De Luca A, Antinori A, Castagna A, Puoti M, d'Arminio Monforte A, the Icona Fndn Study Group. 2011. Role of immune activation and microbial translocation in liver disease progression in HIV/HCV co-infected antiretroviral-naïve patients with high CD4+ count, abstr 936. Abstr. 18th Conf. Retroviruses Opportun. Infect., Boston, MA.
140. Ross AC, Rizk N, O'Riordan MA, Dogra V, El-Bejjani D, Storer N, Harrill D, Tungsiripat M, Adell J, McComsey GA. 2009. Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy. Clin. Infect. Dis. 49:1119-1127.
141. Calmy A, Gayet-Ageron A, Montecucco F, Nguyen A, Mach F, Burger F, Ubolyam S, Carr A, Ruxungtham K, Hirschel B, Ananworanich J, STACCATO Study Group. 2009. HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial. AIDS 23:929-939.
142. Mangili A, Polak JF, Quach LA, Gerrior J, Wanke CA. 2011. Markers of atherosclerosis and inflammation and mortality in patients with HIV infection. Atherosclerosis 214:468-473.
143. Stoll LL, Denning GM, Weintraub NL. 2004. Potential role of endotoxin as a proinflammatory mediator of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 24:2227-2236.
144. Libby P. 2002. Inflammation in atherosclerosis. Nature 420:868-874.
145. Kiechl S, Egger G, Mayr M, Wiedermann CJ, Bonora E, Oberhollenzer F, Muggeo M, Xu Q, Wick G, Poewe W, Willeit J. 2001. Chronic infections and the risk of carotid atherosclerosis: prospective results from a large population study. Circulation 103:1064-1070.
146. Wiedermann CJ, Kiechl S, Dunzendorfer S, Schratzberger P, Egger G, Oberhollenzer F, Willeit J. 1999. Association of endotoxemia with carotid atherosclerosis and cardiovascular disease: prospective results from the Bruneck study. J. Am. Coll. Cardiol. 34:1975-1981.
147. + patients, abstr 309. Abstr. 18th Conf. Retroviruses Opportun. Infect., Boston, MA.
148. Kelesidis T, Yang O, Kendall M, Hodis H, Currier J. 2012. Biomarkers of microbial translocation and macrophage activation are associated with progression of atherosclerosis in HIV infection: ACTG NWCS 332/ A5078 Study, abstr 122. Abstr. 19th Conf. Retroviruses Opportun. Infect., Seattle, WA.
149. Irvine SL, Hummelen R, Hekmat S, Looman CW, Habbema JD, Reid G. 2010. Probiotic yogurt consumption is associated with an increase of CD4 count among people living with HIV/AIDS. J. Clin. Gastroenterol. 44:e201-e205. doi:10.1097/MCG.0b013e3181d8fba8.
150. Klatt N, Canary L, Sun X, Vinton C, Perkins M, Hazuda D, Lifson J, Haddad E, Estes J, Brenchley J. 2012. Probiotic supplementation of ARV treatment during SIV infection of pigtail macaques results in enhanced GI tract CD4+ T cell frequency and immunological function, abstr 95. Abstr. 19th Conf. Retroviruses Opportun. Infect., Seattle, WA.
151. Sugimoto K, Ogawa A, Mizoguchi E, Shimomura Y, Andoh A, Bhan AK, Blumberg RS, Xavier RJ, Mizoguchi A. 2008. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J. Clin. Invest. 118:534-544.
152. Sereti I, Estes J, Thompson W, Fischl M, Croughs T, Beq S, Yao M, Boulassel R, Lederman M, Routy JP. 2012. Gut mucosa T lymphocyte restoration in chronically HIV+ patients treated with recombinant interleukin- 7, abstr 94. Abstr. 19th Conf. Retroviruses Opportun. Infect., Seattle, WA.
153. Hauser AB, Azevedo IR, Gonçalves S, Stinghen A, Aita C, Pecoits- Filho R. 2010. Sevelamer carbonate reduces inflammation and endotoxemia in an animal model of uremia. Blood Purif. 30:153-158.